Article
Irvine, CA-IntraLase Corp. glided into the public realm in early October with a successful initial public offering (IPO) at the top of its indicated range, selling nearly 7.3 million shares and raising $86.6 million.
Ocular pain in Tibetan Plateau residents: Key findings on dry eye disease during COVID-19
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Harrow expands patient access to eyecare medications with price reductions and GoodRx partnership
Innovation Series: Putting the buzz of large language models in ophthalmology into perspective with Robert T. Chang, MD
CHMP issues positive opinion for the marketing authorization of FYB203, a biosimilar candidate to aflibercept
Understanding cerebral/cortical visual impairment: New insights and advances in diagnosis